Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
Sutro Biopharma (NASDAQ: STRO), a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), has announced a Research Forum to showcase its pipeline of next-generation ADCs.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sutro Biopharma (NASDAQ: STRO), a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), has announced a Research Forum to showcase its pipeline of next-generation ADCs. The event is scheduled for October 10, 2024, at 1:30 p.m. PT / 4:30 p.m. ET and will be accessible via live webcast.
Investors and interested parties can join the presentation by visiting https://ir.sutrobio.com/news-events/ir-calendar. For those unable to attend the live event, an archived replay will be made available on the company's website following the presentation.
This forum represents an opportunity for Sutro Biopharma to highlight its innovative approach to ADC development and provide insights into its near-term pipeline, potentially impacting investor interest and the company's stock performance.
Details
News Market Reaction – STRO
The recorded move for STRO in the trading session of this news was +4.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a Research Forum to highlight its pipeline of next-generation ADCs. The live webcast will be held on Thursday, October 10, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET.
Webcast Information:
To access the live audio webcast on Thursday, October 10, at 1:30 p.m. PT / 4:30 p.m. ET, please go to https://ir.sutrobio.com/news-events/ir-calendar
An archived replay of the webcast will be available on the Company’s website following the live presentation.
About Sutro Biopharma
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.